Imagine some teeny-tiny little scissors. Now, imagine them snipping out “bad” genes that cause disease, and leaving only the good ones behind.

Sound farfetched?

Well, actually, it is not.

In fact, that’s exactly what they’re doing at Cleveland Clinic Children’s, where a Sickle Cell Disease clinical trial involving CRSPR gene editing technology is now underway.

We talked about it, with Dr. Rabi Hanna, who is the Chairman of their Department of Pediatric Hematology, and Principal Investigator on the study:

Dr. Rabi Hanna, Cleveland Clinic Children’s